Published in BMJ on January 05, 1991
The spectrum of action of new immunosuppressive drugs. Clin Exp Immunol (1992) 0.87
Tuberculosis and HIV infection. BMJ (1991) 0.75
Monitoring cyclosporin treatment. BMJ (1993) 0.75
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Contingent genetic regulatory events in T lymphocyte activation. Science (1989) 8.03
A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med (1989) 2.71
A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med (1990) 1.81
Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet (1990) 1.56
Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med (1987) 1.39
Pharmacology of cyclosporine (sandimmune). IV. Pharmacological properties in vivo. Pharmacol Rev (1990) 1.23
Lymphokine gene expression in vivo is inhibited by cyclosporin A. J Exp Med (1990) 1.14
Pharmacology of cyclosporine. VI. Cellular activation: regulation of intracellular events by cyclosporine. Pharmacol Rev (1990) 1.05
Signal transmission pathways and lymphocyte function. Immunol Today (1990) 0.89
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
FK 506: an immunosuppressant for the 1990s? Lancet (1991) 2.80
Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol (1999) 2.48
Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48
FK-506--how much potential? Immunol Today (1989) 2.20
Fatal microcystin intoxication in haemodialysis unit in Caruaru, Brazil. Lancet (1998) 2.06
Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis (1985) 2.02
Cyclosporin A inhibits lymphokine production but not the responses of macrophages to lymphokines. Immunology (1983) 1.99
Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol (2001) 1.95
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86
Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81
Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation. With oarticular reference to the liver. Transplantation (1996) 1.65
Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet (1983) 1.64
Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation (1995) 1.63
Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol (2000) 1.60
The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56
Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J Immunol (1996) 1.53
Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol (1985) 1.52
Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation (1995) 1.51
Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood (2001) 1.47
Effects of liver-derived dendritic cell progenitors on Th1- and Th2-like cytokine responses in vitro and in vivo. J Immunol (2000) 1.47
Pregnancy specific beta1-glycoprotein--a product of the syncytiotrophoblast. Experientia (1976) 1.46
The true clinical significance of renography in nephro-urology. Eur J Nucl Med (1997) 1.46
Scintigraphic evidence of abnormal ureteric peristalsis following urological surgery. Br J Urol (1994) 1.39
Pathological changes developing in the rat during a 3-week course of high dosage cyclosporin A and their reversal following drug withdrawal. Transplantation (1981) 1.38
Toxicity of the immune suppressant cyclosporin A in the rat. J Pathol (1982) 1.38
Tropheryma whippelii DNA in saliva of healthy people. Lancet (1999) 1.38
Immunobiology of cyclosporin A--a review. Aust J Exp Biol Med Sci (1983) 1.31
Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit (1995) 1.30
Spontaneous and iatrogenically augmented leukocyte chimerism in organ transplant recipients. Transplant Proc (1994) 1.29
Modification of delayed-type hypersensitivity reactions to ovalbumin in cyclosporin A-treated guinea-pigs. Immunology (1983) 1.27
Relapsing polychondritis with crescentic glomerulonephritis. Br Med J (1978) 1.25
Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol (1994) 1.25
Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and regulatory T cells. Am J Transplant (2006) 1.24
Fundamental Ca2+ signaling mechanisms in mouse dendritic cells: CRAC is the major Ca2+ entry pathway. J Immunol (2001) 1.23
Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. Transplantation (1998) 1.22
Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant (2013) 1.22
Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol (2001) 1.21
Nitric oxide-mediated vasodilation in human pregnancy. Am J Physiol (1997) 1.20
Evaluation of carrageenan as an immunosuppressive agent and mediator of intravascular coagulation. Biomedicine (1976) 1.20
Dendritic cells and immune regulation in the liver. Gut (2003) 1.19
Biological and clinical significance of pregnancy-associated alpha2-glycorprotein (alpha/-PAG)-a review. Invest Cell Pathol (1981) 1.18
Delivery of rapamycin to dendritic cells using degradable microparticles. J Control Release (2008) 1.17
Generation of DC from mouse spleen cell cultures in response to GM-CSF: immunophenotypic and functional analyses. Immunology (1995) 1.17
Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation (1997) 1.17
Isolation, phenotype, and allostimulatory activity of mouse liver dendritic cells. Transplantation (1994) 1.16
Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol (1997) 1.16
Vasculitis affecting the kidney: presentation, histopathology and long-term outcome. Q J Med (1984) 1.15
New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells. Am J Transplant (2008) 1.14
Cyclosporine: immunology, toxicity and pharmacology in experimental animals. Agents Actions (1984) 1.14
FK-506 and haemolytic uraemic syndrome. Lancet (1990) 1.14
Experimental cyclosporin A nephrotoxicity. Br J Exp Pathol (1982) 1.12
Automatic data reduction and pattern recognition methods for analysis of 1H nuclear magnetic resonance spectra of human urine from normal and pathological states. Anal Biochem (1994) 1.12
Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. Clin Exp Immunol (1990) 1.11
Inhibition of nitric oxide limits infarct size in the in situ rabbit heart. Biochem Biophys Res Commun (1993) 1.11
Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther (2000) 1.10
Cytokine mRNA profiles in mouse orthotopic liver transplantation. Graft rejection is associated with augmented TH1 function. Transplantation (1995) 1.10
Cyclosporine-induced fetotoxicity in the rat. Transplantation (1985) 1.10
Inhibition of nitric oxide synthesis reduces infarct size by an adenosine-dependent mechanism. Circulation (1995) 1.10
Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant (2008) 1.10
Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation (2001) 1.09
Major histocompatibility complex class II antigen (HLA-DR, DQ and DP) expression in human fetal skin. Tissue Antigens (1986) 1.09
Toxicity of various carrageenans in the mouse. Br J Exp Pathol (1976) 1.09
FK 506 inhibition of cyclosporine metabolism by human liver microsomes. Transplant Proc (1991) 1.09
Psychiatric aspects of loin pain/haematuria syndrome. Lancet (1992) 1.08
Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol (2001) 1.08
Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol (1998) 1.07
Effect of carrageenan on activity of the mononuclear phagocyte system in the mouse. Br J Exp Pathol (1978) 1.07
Differentiation between allograft rejection and cyclosporin nephrotoxicity in renal-transplant recipients. Lancet (1985) 1.07
Adhesion molecule expression in psoriatic skin lesions and the influence of cyclosporin A. Clin Exp Immunol (1991) 1.07
Phenotypic and functional characterization of mouse hepatic CD8 alpha+ lymphoid-related dendritic cells. J Immunol (2000) 1.07
Cytokine-activated human mesangial cells generate the neutrophil chemoattractant, interleukin 8. Kidney Int (1991) 1.05
Role of a copper (I)-dependent enzyme in the anti-platelet action of S-nitrosoglutathione. Br J Pharmacol (1996) 1.05
Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity. J Immunol (1997) 1.05
Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation (1999) 1.05
Methylprednisolone pulse therapy in the treatment of polyarteritis nodosa. Postgrad Med J (1977) 1.05
Serum cyclosporin levels, hepatic drug metabolism and renal tubulotoxicity. Biochem Pharmacol (1984) 1.03
The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. Immunology (1990) 1.03
FK-506 enters the clinic. Immunol Today (1990) 1.03
Loin pain and haematuria syndrome: a somatoform disorder. QJM (1995) 1.02
Haemostatic changes in the loin pain and haematuria syndrome: secondary to renal vasospasm? Q J Med (1990) 1.01
Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation (1998) 1.01
Acetone production by methylobacteria. Arch Microbiol (1976) 0.99
Severe unexplained loin pain (loin pain haematuria syndrome): management and long-term outcome. QJM (2007) 0.99
Augmentation of delayed-type hypersensitivity to high dose sheep erythrocytes by cyclosporin A in the mouse: influence of drug dosage and route of administration and analysis of spleen cell populations. Clin Exp Immunol (1988) 0.99
Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. Transplantation (1989) 0.98
Fc receptor-bearing and phagocytic cells in syngeneic tumours of C. parvum- and carrageenan-treated mice. Br J Cancer (1979) 0.98
Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse. Clin Exp Immunol (1983) 0.98
Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta. Transplantation (1998) 0.97
Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. Immunology (1988) 0.97
The outcome of renal denervation for managing loin pain haematuria syndrome. BJU Int (2004) 0.97
Cyclosporin A prevents suppression of delayed-type hypersensitivity in mice immunized with high-dose sheep erythrocytes. Immunology (1987) 0.97
The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production. Transplantation (1993) 0.97
Glomerular thrombi in renal allografts associated with cyclosporin treatment. J Clin Pathol (1985) 0.97
Copper chelation-induced reduction of the biological activity of S-nitrosothiols. Br J Pharmacol (1995) 0.97
Potentiation of tumour growth by carrageenan. Transplantation (1977) 0.97
Dendritic cells and tolerance induction. Clin Exp Immunol (1996) 0.97
High resolution proton magnetic resonance spectroscopy of cyst fluids from patients with polycystic kidney disease. Biochim Biophys Acta (1992) 0.96